Shunjun Fu
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism
Papers in ⓘ
- Hepatology 24
- Hepatocellular Carcinoma Treatment and Prognosis 21
-
- Cancer, Lipids, and Metabolism 8
- MicroRNA in disease regulation 6
- Co-authors
- Baogang Peng (16 shared papers)Shaoqiang Li (15 shared papers)Li‐Jian Liang (7 shared papers)Yunpeng Hua (11 shared papers)Weikai Xiao (5 shared papers)Beichu Guo (3 shared papers)Zihai Li (1 shared paper)Bei Liu (1 shared paper)
- Journals
- BMC Cancer (6 papers)Journal of Visualized Experiments (3 papers)Scientific Reports (2 papers)Oncotarget (2 papers)Anti-Cancer Agents in Medicinal Chemistry (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Shunjun Fu
44 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 95
- Hepatology 421
- Cancer Research 395
- Oncology 607
- Immunology 221
- Epidemiology 285
Countries citing papers authored by Shunjun Fu
This map shows the geographic impact of Shunjun Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shunjun Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shunjun Fu more than expected).
Fields of papers citing papers by Shunjun Fu
This network shows the impact of papers produced by Shunjun Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shunjun Fu. The network helps show where Shunjun Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Shunjun Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 235 | |
| 2 | 2014 | 189 | |
| 3 | 2016 | 95 | |
| 4 | 2014 | 84 | |
| 5 | 2013 | 72 | |
| 6 | 2015 | 59 | |
| 7 | 2013 | 45 | |
| 8 | 2017 | 45 | |
| 9 | 2016 | 43 | |
| 10 | 2015 | 41 | |
| 11 | 2014 | 39 | |
| 12 | 2014 | 31 | |
| 13 | 2016 | 28 | |
| 14 | 2015 | 25 | |
| 15 | 2020 | 22 | |
| 16 | 2018 | 22 | |
| 17 | 2017 | 19 | |
| 18 | GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. | 2014 | 16 |
| 19 | 2023 | 13 | |
| 20 | 2013 | 13 |
About Shunjun Fu
Shunjun Fu is a scholar working on Hepatology, Cancer Research, Oncology, Molecular Biology and Epidemiology, having authored 48 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer, Lipids, and Metabolism (8 papers), Liver Disease Diagnosis and Treatment (8 papers), Inflammatory Biomarkers in Disease Prognosis (7 papers), MicroRNA in disease regulation (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Circular RNAs in diseases (4 papers). The work is most often cited by research in Hepatology (421 citations), Cancer Research (395 citations), Oncology (607 citations), Immunology (221 citations) and Epidemiology (285 citations). Shunjun Fu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Baogang Peng, Shaoqiang Li, Li‐Jian Liang, Yunpeng Hua, Weikai Xiao, Beichu Guo, Zihai Li, Bei Liu, Jinyu Zhang and Shunli Shen. Their work appears in journals such as BMC Cancer, Journal of Visualized Experiments, Scientific Reports, Oncotarget and Anti-Cancer Agents in Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.